FDA postpones panel for Glaxo's COPD drug as snowstorm advances
(Reuters) - The Food and Drug Administration said on Tuesday it has postponed a meeting of outside advisers scheduled for March 7 to review a drug developed by GlaxoSmithKline Plc and Theravance Inc for chronic obstructive pulmonary disease (COPD).
The agency did not officially give a reason for the postponement but it comes as a major snowstorm bears down on the Northeastern United States, including Washington D.C., where the panelists were due to meet.
The agency said it would post briefing materials related to the drug, to be called Breo if approved in the United States, no later than two days before the next meeting, once announced.
(Reporting By Toni Clarke in Washington)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Pope Francis named Time's Person of the Year |
- Uruguay becomes first country to legalize marijuana trade
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls
Time magazine named Pope Francis as its Person of the Year, crediting him with shifting the message of the Catholic Church. Slideshow